Kelley Lab study of mitochondrially-targeted doxorubicin published in ACS Chemical Biology

Tue, 16 Apr 2013

Doxorubicin, a commonly-used anticancer agent, typically causes damage within cells via its ability to disrupt the function of nuclear topoisomerase.  Targeting this drug to the mitochondria instead allows the drug to maintain activity, but with toxicity that is not affected by the presence of efflux pumps.  This study was recently published in ACS Chemical Biology and a podcast was also recorded describing this work.